Immatics N.V. (IMTX) reported a wider-than-expected first-quarter loss of $0.50 per share and revenue that missed estimates, as the company increased spending on clinical trials for its cancer therapies.
"Immatics is entering a pivotal period as we continue to progress toward the pre-specified interim and final analyses from the Phase 3 SUPRAME trial of anzu-cel and actively prepare for commercialization in 2027,” Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics, said in a statement.
The German biopharmaceutical company posted revenue of $8.91 million for the quarter ended March 31, a 54 percent decrease from the $19.55 million reported in the same period a year ago. The quarterly loss of $0.50 per share missed the Zacks Consensus Estimate of a $0.42 loss and widened from a $0.35 per share loss a year ago.
Despite the earnings miss, the company's focus remains on its late-stage pipeline, particularly its PRAME franchise targeting a protein expressed in more than 50 cancer types. Investors will be watching for multiple clinical readouts expected in 2026 to validate the platform's potential ahead of a planned 2027 commercial launch for its lead candidate, anzu-cel.
The company's net loss for the first quarter was $66.5 million, a significant shift from a net profit of $45.9 million in the prior-year quarter, which had benefited from higher recognition of non-cash revenue.
Research and Development (R&D) expenses were $68.1 million, a 41 percent increase from $48.2 million a year ago, which the company attributed primarily to costs associated with advancing its clinical trials. General and administrative expenses also rose to $16.7 million, driven by early commercial activities. Immatics ended the quarter with a cash position of $521.5 million.
Immatics is advancing a diversified portfolio built around its PRAME-targeting therapies. The lead asset, anzu-cel (IMA203), is in a Phase 3 trial for advanced cutaneous melanoma and is expected to be the company's first therapy to market.
Beyond melanoma, the company is developing its second-generation cell therapy, IMA203CD8, for a tumor-agnostic approach, and a bispecific antibody, IMA402, for earlier-line cancers. Ahead of the earnings release, the estimate revisions trend for Immatics was favorable, translating into a Zacks Rank #2 (Buy) for the stock.
The wider loss and revenue miss highlight the costs of advancing a late-stage pipeline. The company's value now hinges on delivering positive clinical data from its upcoming readouts in 2026 to justify the increased spending and maintain investor confidence for its 2027 commercialization goal.
This article is for informational purposes only and does not constitute investment advice.
